ArticleCancer genomics & proteomics
Immunoliposome for Ewing Sarcoma.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimMetastatic Ewing sarcoma (EWS) causes high mortality. Precision medicine can help to mitigate dismal outcomes by targeted and more effective eradication of cancer cells. The aim of the study was to propose a targeted immunoliposome (IL) that has a potential of selectively binding to and destroying EWS cells. EWS expresses CD99 used for diagnostics. If CD99 is used for targeted IL, its payload must be more damaging to EWS than normal cells, which may also express CD99. Poly(ADP-ribose) polymerase (PARP) inhibitors are potential payload candidates, since they may enhance apoptosis of EWS-cells treated with DNA-damaging agents. MATERIALS AND
methodsThe R2 genomics platform was used to explore the differential expression of CD99 and PARP1 in seven different databases (two EWS and five various normal tissues). Kaplan-Meier analysis was conducted for prognostic significance of PARP1 expression. The side-effect profile of PARP inhibitors allowed selection of a potential payload for proposed IL.
resultsEWS samples (Savola/Surdez, n=196) had higher CD99 expression than 737 normal tissues. Endothelial compartment had twice-higher CD99 compared to other normal tissues but lower CD99 and PARP1 than EWS. Recurrent/metastatic EWS expressed more PARP1 than primary tumors (ANOVA
conclusionImmunoliposomes covered with anti-CD99 mAbs and loaded with small-molecule niraparib may be developed as an adjuvant therapy for advanced EWS. Projected 100 nm IL should provide vascular permeability and tumor tropism; however, extensive preclinical evaluations will also be required regarding hematopoietic and endothelial damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.